National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
476
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

TABLE G Saw Palmetto: Related Substances That Might Suggest Risk

Related Substance

Safety Issues

Functionally related therapeutic substancesabc

Steroid 5-α-reductase inhibitorsd

Pregnancy category X: Dutasteride is contraindicated for use in women (GlaxoSmithKline, 2001). Finasteride is contraindicated in pregnancy or in women who may become pregnant (Medical Economics Co., 2003) and is classified as not intended for use by women (Medsafe, 2001). Possible adverse effect: low plasma level of DHT caused by exposure of women to dutasteride may inhibit fetal development of male external genitalia and internal reproductive organs (GlaxoSmithKline, 2001).

Animal studies

Mice – the maximum tolerated dose of finasteride was 250 mg/kg/d.

Rats, teratogenicity studies – finasteride was not teratogenic in rats (320 mg/kg/d, 24 mo).

Rats, developmental studies – in pregnant rats treated with finasteride (0.1–100 μg/kg/d), male offspring developed hypospadias (penile defect, urethral opening is displaced to the under surface) in a dose-dependent manner (3.6% incidence at 0.1 μg/kg/d; 100% incidence at 100 μg/kg/d). In pregnant rats treated with finasteride (≥ 30 μg/kg/d), male offspring were observed to have smaller prostate, smaller seminal vesicles, delayed preputial/foreskin separation, and transient nipple development as compared to control animals. In pregnant rats treated with finasteride (≥ 3 μg/kg/d), male offspring displayed a decreased anogenital distance. The critical period is day 16 to day 17 during gestation (a total of 21 d in the rat) for male offspring exposed in utero to manifest the effects already described. No developmental effects were observed in female offspring exposed in utero to finasteride at any dose studied.

Rabbits, developmental studies – no developmental defects were observed in rabbit pups exposed to finasteride (up to 100 mg/kg/d) in utero (days 6–18 of gestation).

Monkeys, developmental studies – finasteride (0.8 μg/d, i.v.) was administered to pregnant rhesus monkeys (days 20–100 of gestation); no developmental abnormalities were observed in the male fetuses. In other studies, finasteride (2 mg/kg/d) administered orally to pregnant rhesus monkeys resulted in defects in the formation of the external genitalia of male fetuses; female fetuses were not affected.

Page
476
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)